Pay in 4 interest-free payments of $5.69 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Retatrutide is a once-weekly injectable triple agonist (GLP-1, GIP, and glucagon receptor) developed by Eli Lilly for obesity and type 2 diabetes
Multiple studies have been conducted on people with type 2 diabetes (and pre-diabetes) to assess how restricted eating windows affect blood sugar
Product monograph: including patient medication information, 2021
Lee PDK, Lustig RH, Feldman HA, Glaser Obesity Study Group: Insulin-Like Growth Factor-Binding Protein-1 (IGFBP-1) predicts insulin sensitivity and area-under-the-curve insulin (AUC)
Starbucks lists it as a classic breakfast sandwich with 18g protein , and nutrition databases commonly place it in the mid-300-calorie range depending on market
US$ 29.27
US$ 26.70
US$ 23.76
US$ 23.99
